After the close, Allos Therapeutics, Inc. (Nasdaq: ALTH) announced final results from a pivotal Phase 2 PROPEL trial of pralatrexate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE